Study of Once Daily Levemir (SOLVE™): Insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice

Diabetes, Obesity and Metabolism

Volumn 14, Issue 7, 2012, Pages 654-661

  Khunti, K ^a   Damci, T ^b   Meneghini, L ^c   Pan, C Y ^d   Yale, J F ^e  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b ISTANBUL UNIVERSITY   (Turkey)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d CHINESE PLA GENERAL HOSPITAL   (China)

^e ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Clinical inertia; Epidemiology; Insulin therapy; Observational study; Oral antidiabetic drug therapy; Treatment guidelines; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; SULFONYLUREA DERIVATIVE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; POLAND; PRACTICE GUIDELINE; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL; SEX RATIO; TREATMENT DURATION; UNITED KINGDOM;

EID: 84861860599     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2012.01602.x     Document Type: Article

References (37)

1. Charpentier G, Genes N, Vaur L et al. Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes: a nationwide French survey. Diabetes Metab 2003; 29(2 Pt 1): 152-158.
2. Costi M, Dilla T, Reviriego J, Castell C, Goday A. Clinical characteristics of patients with type 2 diabetes mellitus at the time of insulin initiation: INSTIGATE observational study in Spain. Acta Diabetol 2010; 47(Suppl. 1): 169-175.
3. Currie CJ, Peters JR, Tynan A et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 2010; 375: 481-489.
4. Currie CJ, Gale EA, Poole CD. Estimation of primary care treatment costs and treatment efficacy for people with Type 1 and Type 2 diabetes in the United Kingdom from 1997 to 2007*. Diabet Med 2010; 27: 938-948.
5. McGill M, Felton AM. New global recommendations: a multidisciplinary approach to improving outcomes in diabetes. Prim Care Diabetes 2007; 1: 49-55.
6. Khunti K, Ganguli S. Who looks after people with diabetes: primary or secondary care? J R Soc Med 2000; 93: 183-186.
7. van Avendonk MJ, Gorter KJ, van den Donk M, Rutten GE. Insulin therapy in type 2 diabetes is no longer a secondary care activity in the Netherlands. Prim Care Diabetes 2009; 3: 23-28.
8. Gerstein HC, Miller ME, Genuth S et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011; 364: 818-828.
9. Ziemer DC, Miller CD, Rhee MK et al. Clinical inertia contributes to poor diabetes control in a primary care setting. Diabetes Educ 2005; 31: 564-571.
10. O'Connor PJ. Improving diabetes care by combating clinical inertia. Health Serv Res 2005; 40(6 Pt 1): 1854-1861.
11. Grant R, Adams AS, Trinacty CM et al. Relationship between patient medication adherence and subsequent clinical inertia in type 2 diabetes glycemic management. Diabetes Care 2007; 30: 807-812.
12. Jeavons D, Hungin AP, Cornford CS. Patients with poorly controlled diabetes in primary care: healthcare clinicians' beliefs and attitudes. Postgrad Med J 2006; 82: 347-350.
13. Kunt T, Snoek FJ. Barriers to insulin initiation and intensification and how to overcome them. Int J Clin Pract Suppl 2009; 164: 6-10.
14. Polonsky WH, Hajos TR, Dain MP, Snoek FJ. Are patients with type 2 diabetes reluctant to start insulin therapy? An examination of the scope and underpinnings of psychological insulin resistance in a large, international population. Curr Med Res Opin 2011; 27: 1169-1174.
15. Karter AJ, Subramanian U, Saha C et al. Barriers to insulin initiation: the translating research into action for diabetes insulin starts project. Diabetes Care 2010; 33: 733-735.
16. Eldor R, Raz I. The individualized target HbA1c: a new method for improving macrovascular risk and glycemia without hypoglycemia and weight gain. Rev Diabet Stud 2009; 6: 6-12.
17. Del Prato S. Megatrials in type 2 diabetes. From excitement to frustration? Diabetologia 2009; 52: 1219-1226.
18. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
19. Reaven PD, Moritz TE, Schwenke DC et al. Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis. Diabetes 2009; 58: 2642-2648.
20. Saremi A, Moritz TE, Anderson RJ, Abraira C, Duckworth WC, Reaven PD. Rates and determinants of coronary and abdominal aortic artery calcium progression in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care 2010; 33: 2642-2647.
21. Rodbard HW, Jellinger PS, Davidson JA et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009; 15: 540-559.
22. Jones S, Benroubi M, Castell C et al. Characteristics of patients with type 2 diabetes mellitus initiating insulin therapy: baseline data from the INSTIGATE study. Curr Med Res Opin 2009; 25: 691-700.
23. Calvert MJ, McManus RJ, Freemantle N. Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study. Br J Gen Pract 2007; 57: 455-460.
24. Karter AJ, Moffet HH, Liu J et al. Glycemic response to newly initiated diabetes therapies. Am J Manag Care 2007; 13: 598-606.
25. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004; 27: 1535-1540.
26. Dodd AH, Colby MS, Boye KS, Fahlman C, Kim S, Briefel RR. Treatment approach and HbA1c control among US adults with type 2 diabetes: NHANES 1999-2004. Curr Med Res Opin 2009; 25: 1605-1613.
27. Alvarez GF, Mavros P, Nocea G, Alemao E, Alexander CM, Yin D. Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study. Diabetes Obes Metab 2008; 10(Suppl. 1): 8-15.
28. Huppertz E, Pieper L, Klotsche J et al. Diabetes mellitus in German primary care: quality of glycaemic control and subpopulations not well controlled - results of the DETECT study. Exp Clin Endocrinol Diabetes 2009; 117: 6-14.
29. Harris SB, Ekoe JM, Zdanowicz Y, Webster-Bogaert S. Glycemic control and morbidity in the Canadian primary care setting (results of the diabetes in Canada evaluation study). Diabetes Res Clin Pract 2005; 70: 90-97.
30. Fu AZ, Qiu Y, Davies MJ, Radican L, Engel SS. Treatment intensification in patients with type 2 diabetes who failed metformin monotherapy. Diabetes Obes Metab 2011; 13: 765-769.
31. Davis TM, Davis Cyllene Uwa Edu Au WA, Bruce DG. Glycaemic levels triggering intensification of therapy in type 2 diabetes in the community: the Fremantle Diabetes Study. Med J Aust 2006; 184: 325-328.
32. Ringborg A, Lindgren P, Yin DD, Martinell M, Stalhammar J. Time to insulin treatment and factors associated with insulin prescription in Swedish patients with type 2 diabetes. Diabetes Metab 2010; 36: 198-203.
33. Simons WR, Vinod HD, Gerber RA, Bolinder B. Does rapid transition to insulin therapy in subjects with newly diagnosed type 2 diabetes mellitus benefit glycaemic control and diabetes-related complications? A German population-based study. Exp Clin Endocrinol Diabetes 2006; 114: 520-526.
34. Goodall G, Sarpong EM, Hayes C, Valentine WJ. The consequences of delaying insulin initiation in UK type 2 diabetes patients failing oral hyperglycaemic agents: a modelling study. BMC Endocr Disord 2009; 9: 19.
35. Peyrot M, Rubin RR, Lauritzen T et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005; 28: 2673-2679.
36. Maclean JR, Chapman RH, Ferrufino CP, Krishnarajah G. Drug titration patterns and HbA 1c levels in type 2 diabetes. Int J Clin Pract 2009; 63: 1008-1016.
37. Monnier L, Lapinski H, Colette C. Contributions of fasting and post-prandial plasma glucose increments to the overall diurnal hyperglycaemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003; 26: 881-885.